On 14 November, ALDE Party hosted the next instalment of its Stakeholder Series to discuss key issues surrounding the European pharmaceutical landscape, in collaboration with Eli Lilly and Company.
The event in Brussels entitled “Medical innovation: Competition and patient access” brought together partners and stakeholders from across the European industry.
Opening the discussion, Billy Kelleher MEP from ALDE Party member Fianna Fáil in Ireland said: “We want to have certainty for industry on policy, so they can look into the future and start to invest in new medicines and new technologies to bring into the market at some stage.”
Delighted to host and moderate this morning’s @ALDEParty Stakeholder Event on Medical Innovation. ⚕️💊— Billy Kelleher MEP (@BillyKelleherEU) November 14, 2023
A highly pertinent topic as MEPs have just concluded tabling amendments 📝 to the #PharmaStrategy and negotiations are about to start 💬 pic.twitter.com/LXeI7X7CSQ
“We need to make sure that the best medicines are being made available to the citizens of Europe. For that to happen, there needs to be a timely and streamlined reimbursement process, and we’re not there yet by any means.”
The debate was held on World Diabetes Day, and Elisabeth Dupont, European Regional Manager at the International Diabetes Federation, shared the importance of a new EU pharmaceutical strategy to the diabetes community.
“Diabetes seems to be a condition which is well-known but badly understood. We can improve the current pharmaceutical strategy by making sure patients are engaged at all stages of the development process, starting from early research to the definition of medical needs,” said Dupont.
Thanks @BillyKelleherEU and @ALDEParty for promoting more patient-centric innovation as part of the pharmaceutical strategy on World Diabetes Day! @IDFEuropeBXL @eupatientsforum @EUDiabetesForum #WDD2023 https://t.co/yxcqyoV0CP— Elisabeth Dupont (@ElisabethDupo10) November 14, 2023
Eli Lilly and Company’s Associate Vice-President of International Government Affairs David Talbot stressed that the EU’s pharmaceutical strategy reform remains a key piece of legislation and can make a crucial difference if approached correctly by all parties.
“The amount of research and development in Europe is declining, it’s a very competitive global environment but the pharmaceutical strategy and associated legislation is an opportunity to reverse that trend. What we need to ask ourselves is if the legislation addresses all the needs from a competitive and access standpoint,” said Talbot.
You can watch the event in full below and on YouTube.